For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?

Saved in:
Bibliographic Details
Published in:La revue de medecine interne 2021-05, Vol.42 (5), p.369-370
Main Authors: Lanthier, L, Langlois, M-F, Plourde, M-É, Cauchon, M
Format: Article
Language:eng ; fre
Subjects:
Body Weight
Comorbidity
Diabetes Mellitus, Type 2 - drug therapy
Glucagon-Like Peptides
Humans
Hypoglycemic Agents - therapeutic use
Life Style
Obesity - complications
Obesity - epidemiology
Obesity - therapy
Overweight - complications
Overweight - epidemiology
Overweight - therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1768-3122
DOI:10.1016/j.revmed.2021.03.334